Open-Label CDCA 250 mg TID for Cerebral Thrombosis Xanthomatosis

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Cerebral Thrombosis XanthomatosisOpen-Label CDCA 250 mg TID - Drug
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial tests the effectiveness of an experimental drug for treating migraines in adults and children.

Eligible Conditions
  • Cerebral Thrombosis Xanthomatosis

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Week 4 and Week 16

Week 16
Change in Bile Alcohols.
Change in Urinary Bile Alcohols

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Adult Cohort
1 of 2
Pediatric Cohort
1 of 2

Experimental Treatment

12 Total Participants · 2 Treatment Groups

Primary Treatment: Open-Label CDCA 250 mg TID · Has Placebo Group · Phase 3

Adult CohortExperimental Group · 4 Interventions: Placebo, Rescue Medication CDCA 250 mg TID, Open-Label CDCA 250 mg TID, Blinded CDCA 250 mg TID · Intervention Types: Drug, Drug, Drug, Drug
Pediatric Cohort
Drug
Experimental Group · 1 Intervention: CDCA Weight-Based Dose TID · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: week 4 and week 16

Who is running the clinical trial?

Travere Therapeutics, Inc.Lead Sponsor
18 Previous Clinical Trials
177,299 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: